Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
Creators
- 1. Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Er Road, Shanghai, 20025 (China)
- 2. Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai (China)
- 3. University of Colorado Comprehensive Cancer Center, Aurora, CO 80045 (United States)
Description
To investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated with Ki67 value change after CNB. A retrospective study was carried out on 276 patients with paired CNB and surgically removed samples (SRS). Clinico-pathological factors as well as the surgery time interval (STI) between CNB and surgery were analyzed to determine whether there were factors associated with Ki67 value change after CNB. Five tumor subtypes were classified as follows: Luminal A, Luminal B-HER2-, Luminal B-HER2+, Triple Negative (TN), and HER2+. Ki67 value change was calculated as SRS minus CNB. Mean STI after CNB was 4.5 (1-37) days. Good agreement was achieved for ER, PR, and HER2 evaluation between CNB and SRS. However, Ki67 expression level was significantly higher in SRS compared with CNB samples: 29.1 % vs. 26.2 % (P < 0.001). Both univariate and multivariate analysis demonstrated that STI and molecular subtype were associated with a Ki67 change after CNB. Luminal A tumors experienced more Ki67 elevation than Luminal B-HER2- diseases (6.2 % vs -0.1 %, P = 0.014). Patients with longer STI after CNB had a higher Ki67 increase: -1.1 % within 1-2 days, 2.1 % with 3-4 days, and 5.6 % more than 4 days, respectively (P = 0.007). For TN and HER2+ tumors, the Ki67 change was apt to be 0 with STI ≤ 4 days, while a >7 % Ki67 increase was noticed in patients with STI ≥ 5 days. CNB was accurate in evaluating ER, PR, HER2, and molecular subtype status. Ki67 value significantly increased after CNB, which was associated with STI and molecular subtype. Further translational research needs to consider Ki67 changes following CNB among different breast cancer molecular subtypes. The online version of this article (doi:10.1186/s12885-015-1853-1) contains supplementary material, which is available to authorized users
Availability note (English)
Available from http://dx.doi.org/10.1186/s12885-015-1853-1; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627413Additional details
Identifiers
Publishing Information
- Journal Title
- BMC cancer (Online)
- Journal Volume
- 15
- Journal Page Range
- vp.
- ISSN
- 1471-2407
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47084352
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BIOPSY; MAMMARY GLANDS; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; PHENOBARBITAL; SURGERY
- Descriptors DEC
- ANESTHETICS; ANTICONVULSANTS; AZINES; BARBITURATES; BODY; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; GLANDS; HETEROCYCLIC COMPOUNDS; HYPNOTICS AND SEDATIVES; MATHEMATICS; MEDICINE; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANIC OXYGEN COMPOUNDS; ORGANS; PYRIMIDINES; STATISTICS
Optional Information
- Copyright
- Copyright (c) Chen et al. 2015
- Notes
- PMCID: PMC4627413; PMID: 26514283; PUBLISHER-ID: 1853; OAI: oai:pubmedcentral.nih.gov:4627413